Should the FDA be requiring a Risk Evaluation and Mitigation Strategy for mifepristone? - Ep 147
ACCP JOURNALS - Un podcast de ACCP JOURNALS
Explore the basis for and controversy surrounding the US Food and Drug Administration requiring a Risk Evaluation and Mitigation Strategy (REMS) for mifepristone. Full text of the manuscript is available at: https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/jac5.2034.
